ES2552108T3 - Compuestos flavonoides y usos de los mismos - Google Patents

Compuestos flavonoides y usos de los mismos Download PDF

Info

Publication number
ES2552108T3
ES2552108T3 ES06704987.4T ES06704987T ES2552108T3 ES 2552108 T3 ES2552108 T3 ES 2552108T3 ES 06704987 T ES06704987 T ES 06704987T ES 2552108 T3 ES2552108 T3 ES 2552108T3
Authority
ES
Spain
Prior art keywords
diohf3ha
hemiadipate
flavone
concentration
diohf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06704987.4T
Other languages
English (en)
Spanish (es)
Inventor
Gregory James Dusting
Owen Llewellyn Woodman
Bevyn Jarrott
Clive Newton May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARMARON BIO Pty Ltd
Florey Institute of Neuroscience and Mental Health
Original Assignee
ARMARON BIO Pty Ltd
Florey Institute of Neuroscience and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901214A external-priority patent/AU2005901214A0/en
Application filed by ARMARON BIO Pty Ltd, Florey Institute of Neuroscience and Mental Health filed Critical ARMARON BIO Pty Ltd
Application granted granted Critical
Publication of ES2552108T3 publication Critical patent/ES2552108T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES06704987.4T 2005-03-11 2006-03-10 Compuestos flavonoides y usos de los mismos Expired - Lifetime ES2552108T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005901214A AU2005901214A0 (en) 2005-03-11 Flavonoid compounds and uses thereof
AU2005901214 2005-03-11
PCT/AU2006/000314 WO2006094357A1 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof

Publications (1)

Publication Number Publication Date
ES2552108T3 true ES2552108T3 (es) 2015-11-25

Family

ID=36952879

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06704987.4T Expired - Lifetime ES2552108T3 (es) 2005-03-11 2006-03-10 Compuestos flavonoides y usos de los mismos

Country Status (15)

Country Link
US (1) US8017649B2 (enExample)
EP (1) EP1856085B1 (enExample)
JP (1) JP5380069B2 (enExample)
KR (1) KR101397510B1 (enExample)
CN (1) CN101137639B (enExample)
AU (1) AU2006222556B2 (enExample)
BR (1) BRPI0608402B8 (enExample)
CA (1) CA2601028C (enExample)
DK (1) DK1856085T3 (enExample)
ES (1) ES2552108T3 (enExample)
NZ (1) NZ560633A (enExample)
RU (1) RU2431634C2 (enExample)
SG (1) SG162773A1 (enExample)
WO (1) WO2006094357A1 (enExample)
ZA (1) ZA200707427B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006222556B2 (en) 2005-03-11 2011-09-29 Armaron Bio Pty Ltd Flavonoid compounds and uses thereof
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
MX2009006958A (es) * 2006-12-28 2009-07-09 Limerick Biopharma Inc Metodos y composiciones para tratamiento terapeutico.
KR100930467B1 (ko) * 2007-06-07 2009-12-08 동아제약주식회사 점액분비를 촉진시키는 3',4',5-트리메톡시 플라본 유도체화합물, 그의 제조방법 및 약학적 용도
EP2182801A4 (en) * 2007-07-31 2011-04-13 Limerick Biopharma Inc PYRONANALOGUE COMPOSITIONS AND CORRESPONDING METHODS
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
EP2182957A4 (en) * 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
CN102438614A (zh) * 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
KR101586992B1 (ko) * 2009-03-20 2016-01-20 건국대학교 산학협력단 플라보노이드를 유효성분으로 하는 배아 발생 개선용 조성물 및 그 방법
EP2460810B1 (en) * 2009-07-31 2015-07-15 National University Corporation Okayama University Novel flavanone derivative
US10314810B2 (en) * 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
CN102464642B (zh) * 2010-11-18 2014-04-23 谢联金 一种化合物及其制备方法及其作为饲料添加剂的应用
KR101459712B1 (ko) * 2012-09-10 2014-11-12 건국대학교 산학협력단 야누스 키나아제 3을 활성을 선택적으로 저해하는 플라보노이드 유도체
EP2906578B8 (en) * 2012-10-11 2019-06-26 Armaron Bio Pty Ltd Novel flavonoid compounds and uses thereof
CN102861053B (zh) * 2012-10-27 2013-07-10 南京大学 Houttuynoid D在治疗白血病药物中的应用
CN104592246A (zh) * 2013-10-30 2015-05-06 周亚伟 一种黄酮类化合物及其制备方法和应用
US9260461B2 (en) * 2014-02-03 2016-02-16 Versitech Limited Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof
KR102596106B1 (ko) 2014-06-30 2023-10-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 연령-관련 증상 및 질환의 치료를 위한 케토부티레이트 화합물 및 조성물
CN104387360B (zh) * 2014-11-21 2016-10-05 潍坊医学院 柚皮素脂肪酸酯、其制备方法和以该化合物为活性成分的药物组合物及其应用
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN105153093B (zh) * 2015-08-29 2017-07-21 西南民族大学 一种黄酮类化合物及其制备方法和用途
CN105153254B (zh) * 2015-08-29 2018-03-30 西南民族大学 一种黄酮类化合物
CN106632479B (zh) * 2016-12-22 2018-10-23 贵州大学 O,o’-二烷基-o”-(取代黄酮-3-基)磷酸酯类衍生物、制备方法及应用
US11185527B2 (en) 2017-06-26 2021-11-30 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent cancers
CN107382941B (zh) * 2017-07-10 2020-05-08 石家庄学院 黄酮衍生物及其制备方法和应用
WO2019016189A1 (en) * 2017-07-18 2019-01-24 Pvac Medical Technologies Ltd ANTIBACTERIAL SUBSTANCE AND COMPOSITION THEREOF, MEDICAL AND NON-MEDICAL USES USING THE SAME, AND PRODUCTS COMPRISING SAID SUBSTANCE AND COMPOSITIONS
CN109280067B (zh) * 2017-07-21 2022-07-05 南京正大天晴制药有限公司 香叶木苷衍生物、其制备方法以及医药用途
CN107550902A (zh) * 2017-10-31 2018-01-09 上海华堇生物技术有限责任公司 黄颜木素的药物用途
CN108752378A (zh) * 2018-07-12 2018-11-06 四川福思达生物技术开发有限责任公司 一种甲基次磷酸单烷基酯的合成方法
CN108997426B (zh) * 2018-07-19 2020-11-13 大连理工大学 靶向Hsp60的黄酮烷氧基氨基磷酸酯衍生物、制备及应用
CN114656579A (zh) * 2020-12-22 2022-06-24 安庆北化大科技园有限公司 一种低毒的黄酮醇磺酸酯类光引发剂及可见光引发体系和应用
CN113045527B (zh) * 2021-03-22 2022-11-08 广东省科学院动物研究所 二氢色原酮衍生物及其合成方法和用途
CN113321633B (zh) * 2021-05-21 2022-03-15 湖北工业大学 槲皮素-3-o-乙酸-(3-氯-4-硫代氨基)-苯酯及在制备糖尿病药物中的应用
CN115504970B (zh) * 2022-10-18 2023-04-18 黑龙江中医药大学 一种用于治疗心肌缺血的黄酮类衍生物及其制备方法
CN116102596B (zh) * 2022-12-13 2026-03-10 黑龙江八一农垦大学 灯盏乙素苷元7位磷酸酯类衍生物及其制备方法及用途
CN119504681B (zh) * 2024-11-27 2025-11-18 河南中烟工业有限责任公司 一种降焦减刺潜香化合物、制备方法、应用及应用方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US650846A (en) * 1899-05-10 1900-06-05 Heiman H Levy Branding-machine.
US3509026A (en) * 1967-01-19 1970-04-28 Litton Systems Inc Method of and apparatus for indicating the sensitivity of microorganisms to antibiotics
GB1461777A (en) * 1973-06-08 1977-01-19 Fisons Ltd 2-phenyl-4-oxo-4h-1-benzopyran derivatives
CA1309672C (en) * 1983-01-27 1992-11-03 Jannis G. Stavrianopoulos Methods and structures employing non-radioactive chemically-labeled polynucleotide probes
DE3442639A1 (de) * 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
US5070018A (en) * 1986-11-07 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Method of controlling gene expression
JPH01153695A (ja) * 1987-12-11 1989-06-15 Showa Denko Kk ルチンまたはケルセチンリン酸エステルの製造法
JPH01308476A (ja) * 1988-06-06 1989-12-13 Showa Denko Kk 紫外線吸収剤
GB8926715D0 (en) * 1989-11-28 1990-01-17 Haessle Ab Improvements relating to the administration of pharmaceutical agents
DE4134384A1 (de) * 1991-10-17 1993-04-22 Ruetgerswerke Ag Modifizierte huminate, verfahren zu ihrer herstellung und verwendung
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
IL112764A0 (en) * 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
FR2719467B1 (fr) * 1994-05-05 1996-05-31 Oreal Utilisation de flavonoïdes pour préserver et/ou renforcer les propriétés mécaniques des cheveux et procédé de protection des cheveux utilisant ces composés.
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
US6921776B1 (en) * 1996-02-16 2005-07-26 Sterix Limited Compound
US6506792B1 (en) * 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
FR2764889B1 (fr) 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6180661B1 (en) * 1997-04-28 2001-01-30 Marigen, S.A. Bioflavonol-glycoside peresters and their incorporation into pharmacologically active concentrates and ultramicroemulsions
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
FR2778663B1 (fr) * 1998-05-15 2001-05-18 Coletica Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire
ES2263213T3 (es) * 1998-06-18 2006-12-01 Consiglio Nazionale Delle Ricerche Procedimiento biocatalitico para la preparacion de 3-acil flavonoides.
EP1109800A1 (en) 1998-09-01 2001-06-27 Lg Chemical Limited Novel cdk inhibitors having flavone structure
WO2000023073A1 (en) * 1998-10-20 2000-04-27 Korea Institute Of Science And Technology Bioflavonoids as plasma high density lipoprotein level increasing agent
CA2358967A1 (en) 1999-01-27 2000-08-03 Zielinski Laboratory Hesperitin pro-forms with enhanced bioavailability
EP1055408A1 (de) * 1999-05-26 2000-11-29 Nutrinova Nutrition Specialties & Food Ingredients GmbH Sorbatkonservierte Mittel, Verfahren zu deren Herstellung und ihre Verwendung
AU6174900A (en) * 1999-07-08 2001-01-30 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
EP1214308A2 (en) * 1999-09-23 2002-06-19 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
DE10003786A1 (de) * 2000-01-28 2001-08-02 Merck Patent Gmbh Galenische Formulierung
EP1127572A3 (en) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Use of flavones for treating cycloxygenase-2 mediated diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EP1136073A1 (en) * 2000-03-22 2001-09-26 N.V. Nutricia Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress
EP1147764A3 (en) * 2000-04-19 2002-03-20 Nof Corporation Cosmetic composition
DE10031457C2 (de) * 2000-06-28 2002-12-12 Jean Krutmann Verwendung von O-beta-Hydroxyethylrutosid oder dessen Aglycon zur systemischen Behandlung und Prophylaxe von UV-induzierten Dermatosen und unerwünschten Langzeitfolgen von UV-Bestrahlungen
ES2263643T3 (es) * 2000-07-28 2006-12-16 Immupharm Aps Uso de hidroxietilrutosidos para el tratamiento de los sintomas del r esfriado comun, de la fiebre de heno y de infecciones relacionadas con el tacto respiratorio.
DE10056400A1 (de) * 2000-11-14 2002-05-23 Merck Patent Gmbh Galenische Formulierung
FR2820974B1 (fr) * 2001-02-21 2004-02-13 Pharmascience Lab Composition topique comprenant une solution vraie contenant un derive de chromane ou de chromene, son procede de preparation et son utilisation cosmetique et therapeutique
JP3691764B2 (ja) * 2001-03-07 2005-09-07 オリンパス株式会社 オートクレーブ装置
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
UY26816A1 (es) * 2001-07-04 2003-04-30 Horacio Heinzen Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo.
FI20011507A0 (fi) 2001-07-10 2001-07-10 Orion Corp Uusia yhdisteitä
CN1668287B (zh) * 2001-09-06 2012-03-28 赛诺克思公司 3-脱氧类黄酮在制备抑制t淋巴细胞活性的药物中的用途
ITRM20010600A1 (it) * 2001-10-04 2003-04-04 Brane Tech S R L Composti flavonoidici capaci di modificare lo stato fisico e/o dinamico di membrane biologiche e di stimolare la sintesi endogena di protein
GB0125532D0 (en) 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
US20050215493A1 (en) * 2002-05-01 2005-09-29 Masaki Miyake Calcium-containing tissue strengthening agents and use thereof
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
DE10244282A1 (de) * 2002-09-23 2004-04-01 Merck Patent Gmbh Zubereitung mit antioxidanten Eigenschaften
AU2003263162B2 (en) * 2002-10-24 2009-05-07 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
KR20050095859A (ko) * 2003-02-04 2005-10-04 가부시키가이샤 야쿠루트 혼샤 유방암 내성 단백 저해제
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
WO2005037300A1 (en) * 2003-10-09 2005-04-28 Medigene Ag The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
JP2007509035A (ja) * 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
KR20070020036A (ko) * 2004-05-18 2007-02-16 브라이트 퓨처 파마수티컬 라보라토리스 리미티드 수면 장애를 위한 조성물
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20060105967A1 (en) * 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
AU2006222556B2 (en) 2005-03-11 2011-09-29 Armaron Bio Pty Ltd Flavonoid compounds and uses thereof
TWI282276B (en) * 2005-04-12 2007-06-11 Univ Taipei Medical Pharmaceutical composition containing flavonoids which possess selective inhibition on phosphodiesterase 4 or 3/4
EP1803809A3 (en) * 2005-08-12 2007-12-19 Abgenomics Corporation Modulation of peroxisome proliferator-activated receptors
WO2007082178A2 (en) 2006-01-06 2007-07-19 Abgenomics Corporation Prostaglandin reductase inhibitors

Also Published As

Publication number Publication date
KR20070114315A (ko) 2007-11-30
ZA200707427B (en) 2008-11-26
JP5380069B2 (ja) 2014-01-08
SG162773A1 (en) 2010-07-29
CN101137639A (zh) 2008-03-05
NZ560633A (en) 2011-08-26
RU2007137659A (ru) 2009-04-20
EP1856085B1 (en) 2015-07-08
BRPI0608402A2 (pt) 2009-12-29
BRPI0608402B8 (pt) 2021-05-25
RU2431634C2 (ru) 2011-10-20
BRPI0608402B1 (pt) 2020-10-13
EP1856085A4 (en) 2010-11-03
WO2006094357A1 (en) 2006-09-14
US8017649B2 (en) 2011-09-13
CA2601028C (en) 2014-05-27
AU2006222556A1 (en) 2006-09-14
AU2006222556B2 (en) 2011-09-29
JP2008532951A (ja) 2008-08-21
DK1856085T3 (en) 2015-10-05
CN101137639B (zh) 2012-05-23
KR101397510B1 (ko) 2014-05-22
US20090130051A1 (en) 2009-05-21
CA2601028A1 (en) 2006-09-14
EP1856085A1 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
DK1856085T3 (en) FLAVONOID COMPOUNDS AND APPLICATIONS THEREOF
ES2062102T5 (es) Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
PT820432E (pt) Esteres do acido 5-aminolevulinico como agentes fotossensibilizadores em fotoquimioterapia
DK2297115T3 (en) DIALCOXYQUINAZOLINE DERIVATIVES AS KDR INHIBITORS
BRPI0712101A2 (pt) ácido beta-fenil-alfa-hidróxi propanóico substituìdo, método de sìntese e uso do mesmo
ES2498828T3 (es) Utilización de derivados de quinazolinas para enfermedades neurodegenerativas
US20190022044A1 (en) Salts of 5-aminolevulinic acid and derivatives
Nakamura et al. Effects of edaravone on experimental brain injury in view of free radical reaction
US20240374584A1 (en) Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
KR20120014788A (ko) 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물
WO2023147196A2 (en) Ph-sensitive fluorophores
CN102336790B (zh) 一氧化氮供体型虎杖苷衍生物、制备方法及医药用途
EA019584B1 (ru) Холиновые соли янтарной кислоты для лечения депрессий, тревоги, шизофрении, нарушений сна и эпилепсии
JP6567419B2 (ja) 新規フラボノイド化合物およびその使用
ES2210009T3 (es) Derivados de benzopiranil-guanidina, proceso para su obtencion y composiciones farmaceuticas que los contienen.
EA022275B1 (ru) Применение рацематов пиноцембрина для получения лекарственных средств для лечения инсульта
CN115956079B (zh) 作为用于治疗新生儿缺氧缺血性脑损伤及相关疾病的药物的嘌呤衍生物
ES2958970T3 (es) Composiciones para uñas con propiedades antifúngicas
CN121818659A (zh) 一种天然衍生物在制备治疗心肌病和/或心肌纤维化药物中的应用
CN121002195A (zh) 以细胞内自由基为特征的病症的诊断、监测和治疗
HK40060534B (en) Use of aminothiol compounds as cerebral nerve or heart protective agent
OA21243A (en) Compounds for treatment of alzheimer's disease.
JP2011527290A (ja) ２−（α−ヒドロキシ−ペンチル）安息香酸カリウムを用いたアルツハイマー病の予防と／またおよび／または治療においての役割への適用
PT91816B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de prostaglandinas para tratamento de glaucoma ou hipertensao ocular